FrancophonIA/ELRC3.0 huggingface dataset:
English: • Passing much more or much less urine than usual, which may be a symptom of a type of kidney problem (called renal tubular necrosis)
Croatian: • mokrenje mnogo veće ili mnogo manje količine mokraće nego što je uobičajeno što može biti simptom vrste oštećenja bubrega (naziva se nekroza bubrežnih tubula)
English: What you need to know before you take Lenalidomide Accord Do not take Lenalidomide Accord :
Croatian: Što morate znati prije nego počnete uzimati Lenalidomid Accord
English: The following post-marketing adverse reactions have been reported (frequency unknown): acute hepatic failure and cholestasis (both potentially fatal), toxic hepatitis, cytolytic hepatitis, mixed cytolytic/cholestatic hepatitis.
Croatian: Nakon stavljanja lijeka u promet, prijavljene su sljedeće nuspojave (učestalost nepoznata): akutno zatajenje jetre i kolestaza (oboje s mogućim smrtnim ishodom), toksični hepatitis, citolitički hepatitis, mješoviti citolitički/kolestatski hepatitis.
English: How to store Lenalidomide Accord 6.
Croatian: Kako čuvati Lenalidomid Accord 6.
English: Lenalidomide Accord contains lactose.
Croatian: Lenalidomid Accord sadrži laktozu.
English: For each subsequent drop below < 0.5 x 109/L
Croatian: Za svaki sljedeći pad ispod < 0,5 x 109/L
English: Common Hyperthyroidism
Croatian: Često hipertireoidizam
English: Grade 3 or 4 thrombocytopenia was observed to a lesser extent in the Rd and Rd18 arms than in the comparator arm (8.1% vs 11.1%, respectively).
Croatian: Trombocitopenija 3. ili 4. stupnja opažena je u manjem opsegu u skupinama koje su primale Rd i Rd18 nego u skupini koja je primala komparator (8,1 % naspram 11,1 %).
English: Cerebrovascular accident◊, Dizziness, Syncope
Croatian: Često cerebrovaskularni događaj◊, omaglica, sinkopa
English: The recommended starting dose is lenalidomide 10 mg orally once daily on days 1 to 21 of repeated 28-day cycles for up to 9 cycles, melphalan 0.18 mg/kg orally on days 1 to 4 of repeated 28-day cycles, prednisone 2 mg/kg orally on days 1 to 4 of repeated 28-day cycles.
Croatian: Preporučena početna doza je lenalidomid 10 mg jednom dnevno peroralno, od 1. do 21. dana u ponavljajućim 28-dnevnim ciklusima do 9 ciklusa, melfalan 0,18 mg/kg peroralno od 1. do 4. dana u ponavljajućim 28-dnevnim ciklusima, prednizon 2 mg/kg peroralno, od 1. do 4. dana u ponavljajućim28-dnevnim ciklusima.
English: The PFS benefit was less in the subgroup of patients with CR than in the subgroup of patients who had not achieved a CR.
Croatian: Korist u smislu preživljenja bez napredovanja bolesti bila je manja u podskupini bolesnika s potpunim odgovorom nego u skupini bolesnika koji nisu postigli potpuni odgovor.
English: Lenalidomide has been used in clinical trials in multiple myeloma patients up to 91 years of age (see section 5.1).
Croatian: Trenutno dostupni farmakokinetički podaci opisani su u dijelu 5.2. Lenalidomid se primjenjivao u kliničkim ispitivanjima bolesnika s multiplim mijelomom starosti do 91 godine (vidjeti dio 5.1).
English: In both studies, patients in the lenalidomide/dexamethasone (len/dex) group took 25 mg of lenalidomide orally once daily on days 1 to 21 and a matching placebo capsule once daily on days 22 to 28 of each 28-day cycle.
Croatian: U oba ispitivanju bolesnici liječeni lenalidomidom/deksametazonom (len/deks) uzimali su 25 mg lenalidomida peroralno jednom dnevno od 1. do 21. dana te odgovarajuću kapsulu placeba jednom dnevno od 22. do 28. dana u svakom 28-dnevnom ciklusu.
English: Patients were randomised 1:1 within 90-100 days after ASCT to receive either lenalidomide or placebo maintenance.
Croatian: Unutar 90-100 dana poslije transplantacije autolognih matičnih stanica, bolesnici su randomizirani 1:1 u skupine koje su kao terapiju održavanja primale ili lenalidomid ili placebo.
English: The recommended dose of dexamethasone is 40 mg orally once daily on days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy and then 40 mg once daily on days 1 to 4 every 28 days.
Croatian: Preporučena doza deksametazona je 40 mg peroralno jednom dnevno od 1. do 4., od 9. do 12. i od 17. do 20. dana svakog 28-dnevnog ciklusa tijekom prva 4 ciklusa terapije i potom 40 mg jednom dnevno od 1. do 4. dana svakih 28 dana.
English: Ischemia, Peripheral ischemia, Intracranial venous sinus thrombosis
Croatian: Manje često ishemija, periferna ishemija, tromboza intrakranijalnog venskog sinusa
English: Patients with known risk factors - including prior thrombosis - should be closely monitored, and action should be taken to try to minimize all modifiable risk factors (eg.
Croatian: Bolesnike s utvrđenim čimbenicima rizika, uključujući i prethodnu trombozu, treba pomno nadzirati i poduzeti mjere kako bi se smanjili svi promjenjivi čimbenici rizika (npr. pušenje, hipertenzija i hiperlipidemija).
English: Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with lenalidomide in combination with low dose dexamethasone
Croatian: Novodijagnosticirani multipli mijelom: bolesnici koji nisu prikladni za transplantaciju liječeni lenalidomidom u kombinaciji s niskom dozom deksametazona
English: • Educational Health Care Professional's kit
Croatian: • edukacijski materijal za zdravstvene radnike
English: Common Deafness (Including Hypoacusis), Tinnitus
Croatian: Poremećaji uha i labirinta Često gluhoća (uključujući hipoakuziju), tinitus
English: Multiple myeloma: patients with at least one prior therapy
Croatian: Multipli mijelom: bolesnici uz najmanje jednu prethodnu terapiju
English: In patients receiving lenalidomide in combination with dexamethasone until progression or for 18 months, the hematologic SPM incidence rate (0.16 per 100 person-years) was not increased as compared to thalidomide in combination with melphalan and prednisone (0.79 per 100 person-years).
Croatian: U bolesnika koji su primali lenalidomid u kombinaciji s deksametazonom do napredovanja bolesti ili tijekom 18 mjeseci, stopa incidencije drugih primarnih hematoloških zloćudnih bolesti (0,16 na 100 osoba-godina) nije bila povećana u usporedbi s talidomidom u kombinaciji s melfalanom i prednizonom (0,79 na 100 osoba-godina).
English: Lenalidomide Accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.
Croatian: Lenalidomid Accord kao monoterapija indiciran je za terapiju održavanja u odraslih bolesnika s novodijagnosticiranim multiplim mijelomom (MM) u kojih je provedena transplantacija autolognih matičnih stanica (engl. autologous stem cell transplantation, ASCT).
English: Haematuria^, Urinary retention, Urinary incontinence
Croatian: Često hematurija^, retencija mokraće, inkontinencija mokraće
English: Grade 4 febrile neutropenia episodes were observed infrequently (1.7% in MPR+R/MPR+p treated patients compared to 0.0 % in MPp+p treated patients; see section 4.8).
Croatian: Epizode febrilne neutropenije 4. stupnja rijetko su opažene (1,7 % u bolesnika liječenih kombinacijom MPR+R/MPR+p u usporedbi s 0,0 % u bolesnika liječenih s MPp+p; vidjeti dio 4.8).
English: This increase was not observed in clinical trials of newly diagnosed multiple myeloma in patients taking lenalidomide in combination with low dose dexamethasone compared to thalidomide in combination with melphalan and prednisone.
Croatian: Opaženi porast nije primijećen u kliničkim ispitivanjima novodijagnosticiranog multiplog mijeloma u bolesnika koji su primali lenalidomid u kombinaciji s niskom dozom deksametazona, u usporedbi s talidomidom u kombinaciji s melfalanom i prednizonom.
English: Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with lenalidomide in combination with melphalan and prednisone
Croatian: Novodijagnosticirani multipli mijelom:bolesnici koji nisu prikladni za transplantaciju liječeni lenalidomidom u kombinaciji s melfalanom i prednizonom
English: The results of PFS at unblinding, following a preplanned interim analysis, using a cut-off of 7 July 2010 (31.4 months follow up) showed a 48% reduction in risk of disease progression or death favoring lenalidomide (HR = 0.52; 95% CI 0.41, 0.66; p <0.001).
Croatian: Rezultati PFS-a pri otkrivanju slijepe šifre ispitivanja, nakon prethodno planirane interim analize, do zaključnog datuma podataka 7. srpnja 2010. (praćenje u trajanju od 31,4 mjeseci) pokazali su smanjeni rizik progresije bolesti ili smrti od 48 % u korist lenalidomida (HR = 0,52; 95 % CI 0,41; 0,66; p <0,001).
English: Physicians should carefully evaluate patients before and during treatment using standard cancer screening for occurrence of SPM and institute treatment as indicated.
Croatian: Liječnici trebaju pažljivo procijeniti bolesnike prije i tijekom liječenja uporabom standardnih testova probira na pojavu drugih primarnih zloćudnih bolesti i započeti liječenje prema potrebi.
English: Co-administration of lenalidomide does not alter the pharmacokinetics of temsirolimus.
Croatian: Istodobna primjena lenalidomida (25 mg) ne mijenja farmakokinetiku temsirolimusa.
English: Very Common Cataracts, Blurred vision Common
Croatian: Vrlo često katarakte, zamagljen vid Često smanjena oštrina vida
English: Lenalidomide Accord contains lactose
Croatian: Lenalidomid Accord sadrži laktozu
English: • Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with lenalidomide in combination with melphalan and prednisone The combination of lenalidomide with melphalan and prednisone in clinical trials of newly diagnosed multiple myeloma patients is associated with a higher incidence of grade 4 neutropenia (34.1% in melphalan, prednisone and lenalidomide arm followed by lenalidomide [MPR+R] and melphalan, prednisone and lenalidomide followed by placebo [MPR+p] treated patients compared with 7.8% in MPp+p-treated patients; see section 4.8).
Croatian: • Novodijagnosticirani multipli mijelom: bolesnici koji nisu prikladni za transplantaciju liječeni lenalidomidom u kombinaciji s melfalanom i prednizonom Kombinacija lenalidomida s melfalanom i prednizonom u kliničkim ispitivanjima bolesnika s novodijagnosticiranim multiplim mijelomom povezana je s većom incidencijom neutropenije 4. stupnja (34,1 % u skupini bolesnika liječenih melfalanom, prednizonom i lenalidomidom, iza čega je slijedio lenalidomid [MPR+R] i bolesnika liječenih melfalanom, prednizonom i lenalidomidom iza čega je slijedio placebo [MPR+p] u usporedbi sa 7,8 % bolesnika liječenih MPp+p; vidjeti dio 4.8).
English: MANUFACTURER (S) RESPONSIBLE FOR BATCH RELEASE
Croatian: PROIZVOĐAČ(I) ODGOVORAN(NI) ZA PUŠTANJE SERIJE LIJEKA U PROMET
English: Severe renal impairment (CLcr < 30 mL/min, not requiring dialysis)
Croatian: Teško oštećenje funkcije bubrega (CLcr < 30 mL/min, nije potrebna dijaliza)
English: • Brochure for male patients
Croatian: • Knjižice za muške bolesnike
English: The risk of ATE is lower in patients with multiple myeloma treated with lenalidomide monotherapy than in patients with multiple myeloma treated with lenalidomide in combination therapy.
Croatian: Rizik od arterijske tromboembolije je manji u bolesnika s multiplim mijelomom liječenih lenalidomidom u monoterapiji nego što je to u bolesnika s multiplim mijelomim liječenih lenalidomidom u kombiniranoj terapiji.
English: Optimal control of co-morbid conditions influencing thyroid function is recommended before start of treatment.
Croatian: Prije početka liječenja preporučuje se optimalna kontrola pridruženih bolesti koje utječu na funkciju štitne žlijezde.
English: Basal cell carcinoma^,◊, Squamous skin cancer^,◊,*
Croatian: Manje često karcinom bazalnih stanica^,◊ rak pločastih stanica kože^,◊,*
English: For men taking lenalidomide lenalidomide passes into human semen.
Croatian: Lenalidomid prolazi u ljudsku spermu.
English: Decrease by one dose level when dosing resumed at next cycle ª If Dose limiting toxicity (DLT) occurs on > day15 of a cycle, lenalidomide dosing will be interrupted for at least the remainder of the current 28-day cycle.
Croatian: Dose Limiting Toxicity, DLT) pojave nakon 15. dana ciklusa, dozu lenalidomida treba privremeno prekinuti barem do kraja tog 28-dnevnog ciklusa.
English: Patients >75 years received a dexamethasone dose of 20 mg once daily on days 1, 8, 15, and 22 of each 28-day cycle.
Croatian: > 75 godina primali su deksametazon u dozi od 20 mg jednom dnevno 1., 8., 15. i 22. dana svakog 28-dnevnog ciklusa.
English: Common Muscular weakness, Joint swelling, Myalgia
Croatian: Često mišićna slabost, oticanje zglobova, mialgija
English: In patients with multiple myeloma, , treatment with lenalidomide monotherapy was associated with a lower risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism) than in patients with multiple myeloma treated with lenalidomide in combination therapy (see sections 4.5 and 4.8).
Croatian: U bolesnika s multiplim mijelomom, monoterapija lenalidomidom bila je povezana s manjim rizikom od venske tromboembolije (pretežno duboke venske tromboze i plućne embolije) nego što je to u bolesnika s multiplim mijelomom liječenih lenalidomidom u kombiniranoj terapiji (vidjeti dijelove 4.5 i 4.8).
English: The median overall survival in the extended follow-up analysis of the pooled studies is 164.3 weeks (95% CI: 145.1, 192.6) in patients treated with len/dex versus 136.4 weeks (95% CI: 113.1, 161.7) in patients treated with placebo/dex.
Croatian: Medijan ukupnog preživljenja u produljenim analizama praćenja udruženih ispitivanja iznosio je 164,3 tjedna (95 % CI: 145,1, 192,6) u bolesnika liječenih kombinacijom len/deks nasuprot 136,4 tjedna (95 % CI: 113,1, 161,7) u bolesnika liječenih placebom/deks.
English: Pneumonia◊, Upper respiratory tract infection◊, Bacterial, viral and fungal infections (including opportunistic infections)◊, Nasopharyngitis, Pharyngitis, Bronchitis◊
Croatian: Vrlo često pneumonija◊, infekcija gornjih dišnih puteva◊, bakterijske, virusne i gljivične infekcije (uključujući oportunističke infekcije)◊, nazofaringitis, faringitis, bronhitis◊
English: The Educational Healthcare Professional's Kit
Croatian: Edukacijski materijal za zdravstvene radnike
English: In clinical trials of newly diagnosed multiple myeloma patients not eligible for transplant, a 4.9-fold increase in incidence rate of hematologic SPM (cases of acute myeloid leukaemia [AML], myelodysplastic syndrome [MDS)]) has been observed in patients receiving lenalidomide in combination with melphalan and prednisone until progression (1.75 per 100 person-years) compared with melphalan in combination with prednisone (0.36 per 100 person-years).
Croatian: U kliničkim ispitivanjima bolesnika s novodijagnosticiranim multiplim mijelomom koji nisu prikladni za transplantaciju, opažena stopa incidencije drugih primarnih hematoloških zloćudnih bolesti (slučajevi akutne mijeloične leukemije [AML], mijelodisplastičnog sindroma [MDS]) bila je 4,9 puta veća u bolesnika koji su primali lenalidomid u kombinaciji s melfalanom i prednizonom do napredovanja bolesti (1,75 na 100 osoba-godina) u usporedbi s onima koji su primali melfalan u kombinaciji s prednizonom (0,36 na 100 osoba-godina).
English: Lenalidomide Accord hard capsules contain lactose.
Croatian: Lenalidomid Accord tvrde kapsule sadrže laktozu.
English: • Pregnancy reporting form
Croatian: • obrazac za prijavu trudnoće.
English: Prednisone
Croatian: Prednizon
English: • That patients should be capable of complying with the requirements for the safe use of
Croatian: • zahtjev da bolesnici trebaju biti sposobni pridržavati se zahtjeva za sigurnu primjenu lijeka Lenalidomid Accord
English: Common Diarrhoea, Vomiting, Nausea
Croatian: Često proljev, povraćanje, mučnina
English: • Multiple myeloma: patients with at least one prior therapy The combination of lenalidomide with dexamethasone in multiple myeloma patients with at least one prior therapy is associated with a higher incidence of grade 4 neutropenia (5.1% in lenalidomide/dexamethasone-treated patients compared with 0.6% in placebo/dexamethasone-treated patients; see section 4.8).
Croatian: • Multipli mijelom: bolesnici uz najmanje jednu prethodnu terapiju Kombinacija lenalidomida s deksametazonom u bolesnika s multiplim mijelomom i najmanje jednom prethodnom terapijom povezana je s višom incidencijom neutropenije 4. stupnja (5,1 % u bolesnika liječenih lenalidomidom/deksametazonom u usporedbi s 0,6 % bolesnika koji su primali placebo/deksametazon; vidjeti dio 4.8).
English: Common Pancytopenia◊
Croatian: Često pancitopenija◊
English: Overall survival Median [95% CI], weeks 1-year Overall survival rate
Croatian: Ukupno preživljenje Medijan [95 % CI], tjedni Jednogodišnja ukupna stopa preživljenja p = 0,045
English: There was no increase in peripheral neuropathy observed with long term use of lenalidomide for the treatment of newly diagnosed multiple myeloma.
Croatian: U dugoročnoj primjeni lenalidomida za liječenje novodijagnosticiranog multiplog mijeloma nije opažen porast u broju perifernih neuropatija.
English: • When lenalidomide is used to treat multiple myeloma in patients who have had a bone marrow transplant.
Croatian: • Ako se lenalidomid koristi za liječenje multiplog mijeloma u bolesnika koji su imali transplantaciju koštane srži, uzima se sam.
English: Leucopenia◊, Lymphopenia
Croatian: leukopenija◊, limfopenija
English: Cases of AML have been observed in clinical trials of newly diagnosed multiple myeloma in patients taking lenalidomide treatment in combination with melphalan or immediately following HDM/ASCT (see section 4.4).
Croatian: Slučajevi akutne mijeloične leukemije (AML) opaženi su u kliničkim ispitivanjima novodijagnosticiranih multiplih mijeloma u bolesnika koji primaju lenalidomid u kombinaciji s melfalanom ili neposredno nakon visoke doze melfalana i transplantacije autolognih matičnih stanica (vidjeti dio 4.4).
English: Hypokalaemia◊, Hyperglycaemia, Hypocalcaemia◊, Decreased appetite, Weight decreased
Croatian: Vrlo često hipokalijemija◊, hiperglikemija, hipokalcijemija◊, smanjeni apetit, smanjena tjelesna težina
English: Complete response (CR), partial response (PR) and overall response (CR+PR) rates in the len/dex arm remain significantly higher than in the placebo/dex arm in both studies.
Croatian: Stope potpunog odgovora, djelomičnog odgovora te ukupnog odgovora u skupini koja je primala len/deks bili su također značajno viši nego u skupini koja je primala placebo/deks u oba ispitivanja.
English: Skin discolouration, Photosensitivity reaction
Croatian: Manje često promjena boje kože, reakcija fotoosjetljivosti
English: How to take Lenalidomide Accord
Croatian: Kako uzimati Lenalidomid Accord
English: Very Common Dyspnoea◊, Epistaxis^
Croatian: Vrlo često dispneja◊, epistaksa^
English: • Appetite lostLow levels of potassium in the blood
Croatian: • niske razine kalija u krvi
English: Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-αand IL-6) by monocytes.
Croatian: T stanica prirodnih ubojica, inhibira angiogenezu blokadom migracije i adhezije endotelnih stanica i stvaranja mikrocirkulacije, povećava stvaranje fetalnog hemoglobina u hematopoetskim matičnim stanicama CD34+ te inhibira stvaranje proupalnih citokina u monocitima (npr. TNF-α i IL-6).
English: In the CALGB 100104 study, the adverse reactions observed more frequently with lenalidomide maintenance than placebo were neutropenia (79.0% [71.9% after the start of maintenance treatment]), thrombocytopenia (72.3% [61.6%]), diarrhoea (54.5% [46.4%]), rash (31.7% [25.0%]), upper respiratory tract infection (26.8% [26.8%]), fatigue (22.8% [17.9%]), leucopenia (22.8% [18.8%]) and anaemia (21.0% [13.8%]).
Croatian: U ispitivanju CALGB 100104, nuspojave opažene češće uz terapiju održavanja lenalidomidom nego placebom bile su neutropenija (79,0 % [71,9 % nakon početka terapije održavanja]), trombocitopenija (72,3 % [61,6 %]), proljev (54,5 % [46,4 %]), osip (31,7 % [25,0 %]), infekcija gornjih dišnih puteva (26,8 % [26,8 %]), umor (22,8 % [17,9 %]), leukopenija (22,8 % [18,8 %]) i anemija (21,0 % [13,8
English: In this pooled extended follow-up analysis, the median TTP was 60.1 weeks (95% CI: 44.3, 73.1) in patients treated with len/dex (N = 353) versus 20.1 weeks (95% CI: 17.7, 20.3) in patients treated with placebo/dex (N = 351).
Croatian: U ovoj udruženoj produljenoj analizi praćenja, medijan vremena do napredovanja bolesti iznosio je 60,1 tjedan (95 % CI: 44,3, 73,1) u bolesnika liječenih kombinacijom len/deks (N = 353) nasuprot 20,1 tjednu (95 % CI: 17,7, 20,3) u bolesnika liječenih placebom/deks (N = 351).
English: • Newly diagnosed multiple myeloma patients
Croatian: • Bolesnici s novodijagnosticiranim multiplim mijelomom
English: In patients with multiple myeloma, the combination of lenalidomide with dexamethasone is associated with an increased risk of arterial thromboembolism (predominantly myocardial infarction and cerebrovascular event) and was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone.
Croatian: U bolesnika s multiplim mijelomom, kombinacija lenalidomida s deksametazonom povezana je s povećanim rizikom od arterijske tromboembolije (pretežno infarkta miokarda i cerebrovaskularnog događaja), a opažena je u manjem opsegu u kombinaciji lenalidomida s melfalanom i prednizonom.
English: • Women who are pregnant.
Croatian: • Trudnoća.
English: • Numbness, tingling or burning sensation to the skin, pains in hands or feet, dizziness, tremor,
Croatian: • utrnulost, trnci ili osjećaj pečenja na koži, bolovi u šakama ili stopalima, omaglica, nevoljno drhtanje, poremećaj okusa
English: Lenalidomide in combination with dexamethasone until disease progression in patients who are not eligible for transplant
Croatian: Primjena lenalidomida u kombinaciji s deksametazonom do napredovanja bolesti u bolesnika koji nisu prikladni za transplantaciju
English: TLS and tumour flare reaction (TFR) have commonly been observed in patients with chronic lymphocytic leukemia (CLL), and uncommonly in patients with lymphomas, who were treated with lenalidomide.
Croatian: Sindrom lize tumora i reakcija razbuktavanja tumora često su opaženi u bolesnika s kroničnom limfocitnom leukemijom, a manje često u bolesnika s limfomima koji su liječeni lenalidomidom.
English: Lenalidomide in combination with melphalan and prednisone followed by maintenance therapy in patients who are not eligible for transplant
Croatian: Lenalidomid u kombinaciji s melfalanom i prednizonom nakon čega slijedi terapija održavanja u bolesnika koji nisu prikladni za transplantaciju
English: • Definition of women of childbearing potential (WCBP) and actions the physician should take if unsure
Croatian: • definicija žena u reproduktivnoj dobi i mjera koje liječnik treba poduzeti ako reproduktivni status bolesnice nije jasan.
English: Vomiting, Abdominal pain upper
Croatian: Često povraćanje, bol u gornjem abdomenu
English: Muscle spasms, Bone pain◊, Musculoskeletal and connective tissue pain and discomfort (including back pain◊), Arthralgia◊
Croatian: Vrlo često mišićni spazmi, bol u kostima◊, bol i nelagoda u mišićno-koštanom i vezivnom tkivu (uključujući bol u leđima◊), artralgija◊
English: Musculoskeletal and Connective Tissue Disorders
Croatian: Poremećaji mišićnokoštanog sustava i vezivnog tkiva
English: Resume lenalidomide at next lower dose level (dose level -2 or -3) once daily.
Croatian: Nastaviti s lenalidomidom pri sljedećoj nižoj razini doze (2. ili 3. razina doze) jednom dnevno